Healionics news

Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.

Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure. An initial human study was c

Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round.

The financing supports the first human study, currently underway, of the company`s innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering the potential to reduce cost and morbidity while improving quality of life among dialysis

Healionics Corporation, a Seattle-based medical device company, has announced the addition of Ryan Takeuchi to its board of directors.
Takeuchi brings 20 years of experience in medical devices and private equity, and most recently served as divisional business leader of W.L. Gore’s Medical Products Division.

“We appreciate Ryan’s vote of confidence in Healionics and our market opportunity, particularly given his insight as recent head of the market leader in our

Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology Officer, is the Principal Investigator for the project.

Phase I of the grant ($440k) has

Healionics’ STARport HD, a novel preclinical stage implantable device that allows needle-free bloodstream access for hemodialysis treatment, has been selected by the American Society of Nephrology (ASN) to be featured at the ASN exhibit booth at Kidney Week 2016 as one of several new technologies portraying the future of kidney disease treatment.

Kidney Week 2016 is the 50th annual kidney research meeting for ASN. This year’s meeting, November 15-20 in Chicago, IL, is expe